A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study

BMC Cancer

Research Article

Sivasai Balivada¹  Deryl L Troyer¹  Masaaki Tamura¹  Marla Pyle¹  Raja Shekar Rachakatla¹  Raj Kumar Dani²  Hongwang Wang²  Thilani N Samarakoon²  Viktor Chikan²  Stefan H Bossmann²  Brandon Walker³  Olga B Koper³  Franklin O Kroh³  Xiaoxuan Leaym³ 

[1] Department of Anatomy and Physiology, Kansas State University, 228 Coles Hall, 66506, Manhattan, KS, USA;Department of Chemistry, Kansas State University, 213 CBC Building, 66506, Manhattan, KS, USA;NanoScale Corporation, 1310 Research Park Drive, 66502, Manhattan, KS, USA;

关键词: Porphyrin;    Intratumoral Injection;    Specific Absorption Rate;    Alternate Magnetic Field;    TCPP;   

DOI  :  10.1186/1471-2407-10-119

 received in 2009-09-01, accepted in 2010-03-30,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThere is renewed interest in magnetic hyperthermia as a treatment modality for cancer, especially when it is combined with other more traditional therapeutic approaches, such as the co-delivery of anticancer drugs or photodynamic therapy.MethodsThe influence of bimagnetic nanoparticles (MNPs) combined with short external alternating magnetic field (AMF) exposure on the growth of subcutaneous mouse melanomas (B16-F10) was evaluated. Bimagnetic Fe/Fe3O4 core/shell nanoparticles were designed for cancer targeting after intratumoral or intravenous administration. Their inorganic center was protected against rapid biocorrosion by organic dopamine-oligoethylene glycol ligands. TCPP (4-tetracarboxyphenyl porphyrin) units were attached to the dopamine-oligoethylene glycol ligands.ResultsThe magnetic hyperthermia results obtained after intratumoral injection indicated that micromolar concentrations of iron given within the modified core-shell Fe/Fe3O4 nanoparticles caused a significant anti-tumor effect on murine B16-F10 melanoma with three short 10-minute AMF exposures. We also observed a decrease in tumor size after intravenous administration of the MNPs followed by three consecutive days of AMF exposure 24 hrs after the MNPs injection.ConclusionsThese results indicate that intratumoral administration of surface modified MNPs can attenuate mouse melanoma after AMF exposure. Moreover, we have found that after intravenous administration of micromolar concentrations, these MNPs are capable of causing an anti-tumor effect in a mouse melanoma model after only a short AMF exposure time. This is a clear improvement to state of the art.

【 授权许可】

Unknown   
© Balivada et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.